Get started

Biologics

Synthetic Biologics Bullish MomentumSynthetic Biologics Announces Washington University School of Medicine in St. Louis IRB Approval of the SYN-004 (ribaxamase) Phase 1b/2a Clinical Protocol. A previously completed placebo-controlled Phase 2b clinical trial of 412 patients demonstrated SYN-004 protected the gut microbiome from antibiotic-mediated dysbiosis. Patients receiving SYN-004 also demonstrated significantly better maintenance and recovery of the gut microbiome as well as lower incidences of new colonization by opportunistic and potentially pathogenic microorganisms such as VRE. (Source: prnewswire.com) Please leave me a message if you want to test the buy and sell indicators that i am using.
SLong
by BuySellMarketMaker
2
BIOL Biolase upside potentialBIOLASE, Inc. is a medical device company, which engages in developing, manufacturing, marketing and sale of laser systems in dentistry and medicine. MITCHELL KOPIN REPORTS 9.6% PASSIVE STAKE IN BIOLASE INC AS OF JULY 22 Armistice Capital Reports 9.99% Passive Stake In Biolase Inc As Of July 21 JACK W. SCHULER REPORTS A 20.54% STAKE IN BIOLASE INC AS OF JUNE 8, 2020 JACK W. SCHULER PREVIOUSLY HELD A 31.17% STAKE IN BIOLASE INC AS OF MAY 13, 2020 4/29/2020 Perkins Capital Management Inc. 1,381,000 $0.52M 0.6% +4.7% 4.373% 2/13/2020 Archon Capital Management LLC 2,675,427 $1.48M 0.3% +61.6% 8.645% You still have time to take this huge buying opportunity! Not trading advice. If you are interested to test some amazing buy and sell indicators, which give the signal at the beginning of the candle, not at the end of it, just leave me a message.
BLong
by TopgOptions
4